Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.05.16
Views: 2795
Rating:

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Alexander Drilon speaks with ecancertv at AACR 2016 on results from phase I trials of entrectinib, a new treatment for TRK fusions with additional effects on Ros1 and Alk.

He reports it as a safe, low toxicity treatment, with significant improvement on patient quality of life.

Dr Drilion advocates further testing of these fusions in patients, with entrectinib now approaching phase II trials.

For more on these results, you can watch his press release here, or for more on TRK fusions, you can watch an interview with Dr David Hong on treating these fusions with LOXO-101.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation